Forecast

The analysts' average price target is €24.61 (+2.71%). The median is €23.56 (-1.67%).

Buy	15
Hold	23
Sell	1

News Go to news feed

Pfizer Lyme vaccine application enters EMA review despite Phase 3 statistical caveat

The EMA has validated the marketing application for PF-07307405, the Pfizer–Valneva Lyme vaccine, and begun formal review. The submission is based on the Phase 3 VALOR trial showing >70% efficacy and no safety signals, but the primary prespecified analysis missed its predefined statistical confidence-bound threshold while a second analysis met it. Approval would leave the partners with little direct competition in Europe, but review timelines, pricing and commercialization details remain uncertain and the market reaction was muted. » More on finance.yahoo.com
Pfizer's 6% dividend looks secure but rests on thin cash flow and heavy debt

Pfizer pays a 6.19% yield that is currently covered by free cash flow, and management has explicitly committed to maintain the payout. COVID-era revenues from Comirnaty and Paxlovid have plunged 59% and 63%, and newly launched products are growing but not yet fully replacing lost sales. The company carries $60.5 billion of long-term debt versus $976 million in cash, and the $2.45 billion quarterly dividend competes directly with debt service; a sustained drop in operating cash flow below the dividend for two quarters would threaten the payout. » More on finance.yahoo.com
Pfizer's dividend likely sustainable despite payout ratio above 100%

Pfizer's dividend appears maintainable because cash flow covers roughly 90% of payouts and the company held about $12.7 billion in cash and short-term investments at end of Q2 2026, enough to fund more than a year of dividend payments. Management has publicly stated it intends to keep the dividend, reducing near-term cut risk. The main concern is revenue pressure from patent expirations and a pipeline shortfall; a dividend cut remains possible in a severe downside but even a large reduction would leave a yield above market levels. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Pfizer has already paid €1.11 in dividends. The last payout was in September.

Financials

In the last quarter, Pfizer had revenue of €13.2B and net profit of -€216.05M

(EUR)	June 2026	YoY
Revenue	13.2B	5.67%
Gross profit	9.61B	19.63%
Net profit	-216.05M	108.71%
EBITDA	1.05B	76.80%

Fundamentals

Metric	Value
Market capitalization	€137.02B
Number of shares	5.7B
52-week high/low	€25.49 - €20.58
Dividend yield	6.19%
Dividends TTM	€1.48
Beta	0.30
P/E ratio	36.40
PEG ratio	-0.61
P/B ratio	1.84
P/S ratio	2.47

Company profile

Pfizer Inc. erforscht, entwickelt, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Medikamente und Impfstoffe in verschiedenen therapeutischen Bereichen an, darunter Herz-Kreislauf-Stoffwechsel- und Frauengesundheit unter den Marken Premarin und Eliquis; Biologika, kleine Moleküle, Immuntherapien und Biosimilars unter den Marken Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena und Braftovi; und sterile injizierbare und antiinfektiöse Arzneimittel sowie orale COVID-19-Behandlung unter den Marken Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga und Paxlovid. Das Unternehmen bietet auch Arzneimittel und Impfstoffe in verschiedenen therapeutischen Bereichen an, wie Pneumokokken, Meningokokken, Zeckenenzephalitis und COVID-19 unter den Marken Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba und der Prevnar-Familie; Biosimilars für chronische Immun- und Entzündungskrankheiten unter den Marken Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis und Cibinqo sowie Amyloidose, Hämophilie und endokrine Erkrankungen unter den Marken Vyndaqel/Vyndamax, BeneFIX und Genotropin. Darüber hinaus ist das Unternehmen im Bereich der Auftragsherstellung tätig. Das Unternehmen beliefert Großhändler, Einzelhändler, Krankenhäuser, Kliniken, Behörden, Apotheken und einzelne Anbieter sowie Zentren für Krankheitskontrolle und Prävention. Das Unternehmen hat Kooperationsvereinbarungen mit Bristol-Myers Squibb Company, Astellas Pharma US, Inc, Myovant Sciences Ltd, Akcea Therapeutics, Inc, Merck KGaA, Valneva SE, BioNTech SE und Arvinas, Inc. Pfizer Inc. wurde 1849 gegründet und hat seinen Hauptsitz in New York, New York.

Name	Pfizer
CEO	Albert Bourla
Headquarters	New York City, ny USA
Website	investors.pfizer.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	02/26/2021
Employees	75,000